AMTX Nasdaq Industrial Organic Chemicals Financials FY2016βFY2025
Aemetis, Inc had $198M of revenue in fiscal 2025, down 26.2% on the year before. Over five years, revenue changed +3.6% a year on average.
Last close Β· Oct 23, 2026
$1.30
8.3%Hi! I read Aemetis, Incβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β26.2%
No. Sales fell 26.2% last year.
Does it make a profit?
β39.0%
No. It lost money last year.
Does profit turn into cash?
β11.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Aemetis, Inc did it, and the next one. Share prices often move a lot on those days.
Next results
November 5, 2026
Thursday Β· in 10 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 6, 2026 | Q2 '26 | Before the market opens | 8-K β |
| May 7, 2026 | Q1 '26 | Before the market opens | 8-K β |
| Mar 12, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Nov 6, 2025 | Q3 '25 | Before the market opens | 8-K β |
| Aug 7, 2025 | Q2 '25 | Before the market opens | 8-K β |
| May 8, 2025 | Q1 '25 | Before the market opens | 8-K β |
| Mar 13, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Nov 12, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Aemetis, Inc had $198M of revenue in fiscal 2025, down 26.2% on the year before. Over five years, revenue changed +3.6% a year on average. Its operating margin was β18.8%, down 3.7Β pts: of every 100 in sales, about β19 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Aemetis, Inc lost $77.0M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$22.7M in fiscal 2025, β11.5% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Aemetis, Inc owes $380M more than it holds in cash.
Cash, debt and the ratios that show how comfortably Aemetis, Inc can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $7.8M | $4.3M | $2.7M | $0.9M | $4.9M |
| Debt incl. finance leases | $206M | $286M | $321M | $368M | $385M |
| Interest coverage | β0.7x | β1.2x | β0.9x | β0.9x | β0.7x |
| Current ratio | 0.3x | 0.2x | 0.4x | 0.3x | 0.1x |
| Quick ratio | 0.2x | 0.2x | 0.2x | 0.1x | 0.0x |
| Total assets | $161M | $207M | $243M | $259M | $260M |
| Total liabilities | $281M | $409M | $460M | $523M | $567M |
| Shareholders' equity | β$120M | β$202M | β$217M | β$264M | β$307M |
| Net debt (β = net cash) | $198M | $282M | $318M | $367M | $380M |
KIRA Β· Its return on capital was β42.0%: every 100 invested in the business earned about β42 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Aemetis, Inc passes 3 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 9 | 3 / 9 | 4 / 9 | 5 / 9 | 3 / 9 | 1 / 9 | 7 / 9 | 2 / 9 | 3 / 9 |
| Accruals ratio | β20.6% | β26.8% | β33.1% | β39.1% | β34.8% | β18.5% | β46.1% | β26.7% | β21.7% | β30.9% |
| Altman Z'' | β7.62 | β8.59 | β10.55 | β11.69 | β13.00 | β9.44 | β10.61 | β9.19 | β11.17 | β18.25 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $143M | $150M | $172M | $202M | $166M | $212M | $28.1M | $77.2M | $268M | $198M |
| Gross profit | $11.6M | $3.4M | $5.4M | $12.7M | $11.0M | $7.9M | β$5.5M | $2.0M | β$0.6M | β$0.8M |
| Research and development | $0.4M | $2.4M | $0.2M | $0.2M | $0.2M | $0.1M | $0.2M | $0.2M | β | β |
| Operating income | β$0.8M | β$12.2M | β$10.9M | β$4.9M | β$6.1M | β$15.8M | β$34.4M | β$37.4M | β$40.4M | β$37.2M |
| Interest expense | $17.2M | $19.3M | $25.7M | $21.1M | $22.9M | $24.1M | $28.8M | $39.5M | $46.6M | $52.9M |
| Pretax income | β$15.6M | β$31.8M | β$36.3M | $0.0M | $0.0M | β$47.3M | β$107M | β$100M | β$98.4M | β$95.7M |
| Income tax | $0.0M | $0.0M | $0.0M | $1.1M | β$1.0M | β$0.1M | $1.1M | β$53.7M | β$10.8M | β$18.7M |
| Net income | β$15.6M | β$31.8M | β$36.3M | β$39.5M | β$36.7M | β$47.1M | β$108M | β$46.4M | β$87.5M | β$77.0M |
| Diluted EPS | β$0.79 | β$1.53 | β$1.63 | β$1.75 | β$1.74 | β$1.54 | β$3.12 | β$1.22 | β$1.91 | β$1.28 |
| Diluted shares | 0.00B | 0.00B | 0.00B | 0.02B | 0.02B | 0.03B | 0.03B | 0.04B | 0.05B | 0.06B |
| Cash flow | ||||||||||
| Cash from operations | $0.4M | β$8.7M | β$5.5M | β$2.0M | $2.5M | β$20.6M | β$22.9M | $13.8M | β$32.9M | $3.3M |
| Capital expenditure | $0.6M | $1.1M | $4.1M | $8.6M | $19.3M | $26.7M | $39.2M | $33.1M | $20.3M | $26.0M |
| Free cash flow | β$0.3M | β$9.8M | β$9.6M | β$10.6M | β$16.9M | β$47.3M | β$62.0M | β$19.3M | β$53.2M | β$22.7M |
| Depreciation and amortization | $4.7M | $4.6M | $4.6M | $4.4M | $4.9M | $5.4M | $5.5M | $6.9M | $8.4M | $9.6M |
| Stock-based compensation | $0.7M | $1.1M | $1.0M | $0.8M | $1.0M | $3.9M | $6.4M | $7.7M | $8.3M | $5.8M |
| Share buybacks | $0.0M | β | β | β | β | β | β | β | β | β |
| Dividends and buybacks | $0.0M | β | β | β | β | β | β | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $1.5M | $0.4M | $1.2M | $0.7M | $0.6M | $7.8M | $4.3M | $2.7M | $0.9M | $4.9M |
| Total debt | $110M | $152M | $173M | $197M | $245M | $204M | $283M | $318M | $365M | $382M |
| Finance lease liabilities | β | β | β | $0.0M | $1.6M | $1.3M | $3.0M | $2.7M | $2.9M | $3.1M |
| Current assets | $7.0M | $11.5M | $10.3M | $12.6M | $8.7M | $20.7M | $18.1M | $36.4M | $44.7M | $26.9M |
| Current liabilities | $27.2M | $36.0M | $42.6M | $57.8M | $102M | $65.3M | $88.3M | $84.4M | $144M | $371M |
| Inventory | $3.2M | $5.7M | $6.1M | $6.5M | $4.0M | $5.1M | $4.7M | $18.3M | $25.4M | $11.6M |
| Property and equipment, net | $66.4M | $78.8M | $78.5M | $84.2M | $110M | $135M | $180M | $195M | β | β |
| Total assets | $77.8M | $94.3M | $91.8M | $99.9M | $125M | $161M | $207M | $243M | $259M | $260M |
| Total liabilities | $128M | $173M | $207M | $254M | $310M | $281M | $409M | $460M | $523M | $567M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | β | β | β | β |
| Shareholders' equity | β$49.8M | β$78.4M | β$116M | β$154M | β$185M | β$120M | β$202M | β$217M | β$264M | β$307M |
| Margins | ||||||||||
| Gross margin | 8.1% | 2.2% | 3.2% | 6.3% | 6.7% | 3.7% | β19.7% | 2.6% | β0.2% | β0.4% |
| Operating margin | β0.5% | β8.1% | β6.4% | β2.4% | β3.7% | β7.5% | β122.4% | β48.5% | β15.1% | β18.8% |
| EBITDA margin | 2.7% | β5.0% | β3.7% | β0.3% | β0.7% | β4.9% | β102.7% | β39.5% | β12.0% | β14.0% |
| Net margin | β10.9% | β21.2% | β21.2% | β19.5% | β22.1% | β22.2% | β383.3% | β60.1% | β32.7% | β39.0% |
| FCF margin | β0.2% | β6.5% | β5.6% | β5.3% | β10.2% | β22.3% | β220.6% | β25.0% | β19.9% | β11.5% |
| Returns | ||||||||||
| Return on capital | β1.1% | β13.2% | β15.4% | β9.4% | β8.1% | β16.4% | β35.4% | β30.0% | β31.9% | β42.0% |
| Return on capital employed | β1.5% | β20.9% | β22.2% | β11.7% | β26.5% | β16.6% | β28.9% | β23.5% | β35.0% | 33.4% |
| Return on assets | β20.1% | β36.9% | β39.0% | β41.2% | β32.6% | β33.0% | β58.6% | β20.6% | β34.8% | β29.7% |
| Growth | ||||||||||
| Revenue growth | β | 4.9% | 14.2% | 17.8% | β18.0% | 28.0% | β86.7% | 174.6% | 246.7% | β26.2% |
| Share count change | β | 0.0% | 2.5% | 100,722.7% | 2.7% | 46.0% | 12.7% | 10.1% | 20.6% | 30.7% |
| Financial health | ||||||||||
| Net debt / EBITDA | 27.8x | β | β | β | β | β | β | β | β | β |
| Interest coverage | β0.0x | β0.6x | β0.4x | β0.2x | β0.3x | β0.7x | β1.2x | β0.9x | β0.9x | β0.7x |
| Current ratio | 0.3x | 0.3x | 0.2x | 0.2x | 0.1x | 0.3x | 0.2x | 0.4x | 0.3x | 0.1x |
| Quick ratio | 0.1x | 0.2x | 0.1x | 0.1x | 0.0x | 0.2x | 0.2x | 0.2x | 0.1x | 0.0x |
| Capital allocation | ||||||||||
| Capex / revenue | 0.4% | 0.7% | 2.4% | 4.2% | 11.7% | 12.6% | 139.3% | 42.9% | 7.6% | 13.2% |
| Stock comp / revenue | 0.5% | 0.7% | 0.6% | 0.4% | 0.6% | 1.9% | 22.8% | 9.9% | 3.1% | 2.9% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 3.0 | 3.0 | 4.0 | 5.0 | 3.0 | 1.0 | 7.0 | 2.0 | 3.0 |
| Altman Z'' | β7.6 | β8.6 | β10.5 | β11.7 | β13.0 | β9.4 | β10.6 | β9.2 | β11.2 | β18.3 |
| Accruals ratio | β20.6% | β26.8% | β33.1% | β39.1% | β34.8% | β18.5% | β46.1% | β26.7% | β21.7% | β30.9% |
Source: SEC EDGAR XBRL filings (CIK 0000738214). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
